Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9554)	4/7/1999 8:06:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Jennifer Doyle responded to my question on what the accrual rates are they were 381 for Meningococcemia and 740 for trauma. I was not correcting you on your near 800 post since I do consider this near. I was really impressed with the product sheets. I am eager to see which company will be the first to license the humanization process. Given that 16 companies have licensed the cell expression technology and others have licensed the diagnostic technology I think the market should eventually catch on that XOMA can do something right. The product sheets represent IMO a team effort at XOMA. I doubt Martin put them together all by her self. If she did great, but I just don't want anyone at XOMA to think many of us don't appreciate the efforts they make to assure shareholders are properly informed. I expect the Sutro presentation by Castello will be constructive for the stock tomorrow. "Constructive" is street talk for I have no idea of what the price of the stock will do but no one can prove it was not constructive. <g>